<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AMOXICILLIN AND CLAVULANATE POTASSIUM- amoxicillin and clavulanate potassiumÂ powder, for suspensionÂ </strong><br><strong>AMOXICILLIN AND CLAVULANATE POTASSIUM- amoxicillin and clavulanate potassiumÂ tablet, chewableÂ </strong><br>Ranbaxy Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
<h1></h1>
</div>
<div class="Section">
<a name="INV-01696cd8-7115-41f6-ab57-77312a4e9608"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><a name="INV-672b7a95-3a75-4709-8138-e596bdc51444"></a><span class="Bold">Rx Only</span></p>
<p><a name="INV-95391610-f691-4f95-8ce3-84589b5971d9"></a>To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-bac9cf4f-3262-41e3-ac03-211ecb49b8ff"></a><a name="section-3"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><a name="INV-cbbbcbe0-dc4b-4ef2-af2d-959eb365ef6a"></a>Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets(chewable) is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the Î²-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Amoxicillin is an analog of ampicillin, derived from the basic penicillin nucleus, 6- aminopenicillanic acid. The amoxicillin molecular formula is C <span class="Sub">16</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">5</span>Sâ€¢3H<span class="Sub">2</span>O, and the molecular weight is 419.46. Chemically, amoxicillin is (<span class="Italics">2S,5R,6R</span>)-6-[(<span class="Italics">R</span>)-(-)-2-Amino-2-(<span class="Italics">p-</span>hydroxyphenyl)acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate and may be represented structurally as:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b897c800-24a2-4e76-8668-498c5515c3d0&amp;name=image_1.JPG"></div>
<p><a name="INV-e6caa2bd-17bc-416f-8cac-a93d1b404560"></a>Clavulanic acid is produced by the fermentation of <span class="Italics">Streptomyces clavuligerus</span>. It is a Î²-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of Î²-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated Î²-lactamases frequently responsible for transferred <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span> to penicillins and cephalosporins. The clavulanate potassium molecular formula is C<span class="Sub">8</span>H<span class="Sub">8</span>KNO<span class="Sub">5</span>, and the molecular weight is 237.25. Chemically, clavulanate potassium is potassium (<span class="Italics">Z </span>)-(<span class="Italics">2R,5R</span>)-3-(2-hydroxyethylidene)-7-oxo-4- oxa-1-azabicyclo[3.2.0]-heptane-2-carboxylate and may be represented structurally as: </p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b897c800-24a2-4e76-8668-498c5515c3d0&amp;name=image_2.JPG"></div>
<p><a name="INV-12029e6e-16e6-4629-a68f-101ca5d91bc9"></a><span class="Bold">Powder for Oral Suspension:</span>Each 5 mL of reconstituted amoxicillin and clavulanate potassium for oral suspension 200 mg/5 mL contains 0.14 mEq potassium. Each 5 mL of reconstituted amoxicillin and clavulanate potassium for oral suspension 400 mg/5 mL contains 0.29 mEq of potassium. <span class="Bold">Inactive Ingredients:</span> Aspartameâ€¢, colloidal silicon dioxide, flavor strawberry, flavor strawberry guarana, monosodium citrate, silicon dioxide, sodium citrate (as dihydrate), xanthan gum.</p>
<p><a name="INV-2896c07b-251c-44ef-99cc-e9bf0688f7dc"></a><span class="Bold">Chewable Tablets:</span>Each 200 mg/28.5 mg chewable tablet contains 0.15 mEq potassium. Each 400 mg chewable tablet contains 0.30 mEq of potassium. <span class="Bold">Inactive Ingredients</span><span class="Bold">:</span> Aspartameâ€¢, FD&amp;C red No. 40 aluminum lake, glycine, povidone, magnesium stearate, mannitol, mint cream flavor, orange cream flavor, silicon dioxide, sodium starch glycolate, tropical blend flavor.</p>
<p><a name="INV-c52871b2-0d5f-488e-bdc2-169d7f1af8b9"></a>â€¢See <span class="Bold">PRECAUTIONS</span>â€“Information for the Patient.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-8ac8238b-3553-4ee5-8933-0da27d8fb4ff"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><a name="INV-f7e3057e-03a2-43b1-a2aa-d630d284c8cd"></a>Amoxicillin and clavulanate potassium are well absorbed from the gastrointestinal tract after oral administration of amoxicillin and clavulanate potassium. Dosing in the fasted or fed state has minimal effect on the pharmacokinetics of amoxicillin. While amoxicillin and clavulanate potassium can be given without regard to meals, absorption of clavulanate potassium when taken with food is greater relative to the fasted state. In 1 study, the relative bioavailability of clavulanate was reduced when amoxicillin and clavulanate potassium was dosed at 30 and 150 minutes after the start of a high-fat breakfast. The safety and efficacy of amoxicillin and clavulanate potassium have been established in clinical trials where amoxicillin and clavulanate potassium was taken without regard to meals.</p>
<p><a name="INV-ff478d41-0389-4afa-b719-eab6169bdc86"></a>Oral administration of single doses of amoxicillin and clavulanate potassium for oral suspension 200 mg/5 mL and 400 mg/5 mL, and amoxicillin and clavulanate potassium tablets (chewable) 200 mg/28.5 mg and 400 mg/57 mg) to 28 adult volunteers yielded comparable pharmacokinetic data:</p>
<a name="INV-eba4648e-e487-43f6-bedc-ce8eddfbb581"></a><table border="1" frame="border">
<col width="184px">
<col width="92px">
<col width="102px">
<col width="92px">
<col width="100px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="center"><span class="Bold">Dose<span class="Sup">*</span></span></td>
<td class="Botrule" align="center" colspan="2">
<span class="Bold">AUC<span class="Sub">0-</span></span><span class="Sub">âˆž</span><span class="Bold">(mcg.hr/mL)</span>
</td>
<td class="Botrule Rrule" align="center" colspan="2"><span class="Bold">C<span class="Sub">max</span> (mcg/mL)<span class="Sup">â€ </span></span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><span class="Bold">(amoxicillin/clavulanate potassium)</span></td>
<td class="Botrule" align="center">
<span class="Bold">amoxicillin</span><span class="Bold">(Â± S.D.)</span>
</td>
<td class="Botrule" align="center">
<span class="Bold">clavulanate </span><span class="Bold">potassium</span><span class="Bold">(Â± S.D.)</span>
</td>
<td class="Botrule" align="center">
<span class="Bold">amoxicillin</span><span class="Bold">(Â± S.D.)</span>
</td>
<td class="Botrule Rrule" align="center">
<span class="Bold">clavulanate </span><span class="Bold">potassium</span><span class="Bold">(Â± S.D.)</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule"> 400 mg/57 mg
 (5 mL of suspension) </td>
<td class="Botrule" align="center"> Â 
 17.29 Â± 2.28 </td>
<td class="Botrule" align="center"> Â 
 2.34 Â± 0.94 </td>
<td class="Botrule" align="center"> Â 
 6.94 Â± 1.24 </td>
<td class="Botrule Rrule" align="center"> Â 
 1.10 Â± 0.42 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"> 400 mg/57 mg
  (one chewable tablet) </td>
<td class="Botrule" align="center"> Â 
 17.24 Â± 2.64 </td>
<td class="Botrule" align="center"> Â 
 2.17 Â± 0.73 </td>
<td class="Botrule" align="center"> Â 
 6.67 Â± 1.37 </td>
<td class="Botrule Rrule" align="center"> Â 
 1.03 Â± 0.33 </td>
</tr>
</tbody>
</table>
<p><a name="INV-3b3d2966-4d67-4f5f-b9a5-9ffe6c14bd6c"></a><span class="Sup">*</span>Administered at the start of a light meal.</p>
<p><a name="INV-aab56142-e8cb-43a3-8c89-af3db82a1a4a"></a><span class="Sup">â€ </span>Mean values of 28 normal volunteers. Peak concentrations occurred approximately 1 hour after the dose.</p>
<p><a name="INV-12c357b6-9bd0-4a6b-9f03-301827385765"></a>Oral administration of 5 mL of amoxicillin and clavulanate potassium 250 mg/5 mL suspension or the equivalent dose of 10 mL amoxicillin and clavulanate potassium 125 mg/5 mL suspension provides average peak serum concentrations approximately 1 hour after dosing of 6.9 mcg/mL for amoxicillin and 1.6 mcg/mL for clavulanic acid. The areas under the serum concentration curves obtained during the first 4 hours after dosing were 12.6 mcg.hr/mL for amoxicillin and 2.9 mcg.hr/mL for clavulanic acid when 5 mL of amoxicillin and clavulanate potassium 250 mg/5 mL suspension or equivalent dose of 10 mL of amoxicillin and clavulanate potassium 125 mg/5 mL suspension was administered to adult volunteers. One amoxicillin and clavulanate potassium 250 mg chewable tablet or two amoxicillin and clavulanate potassium125 mg chewable tablets are equivalent to 5 mL of amoxicillin and clavulanate potassium 250 mg/5 mL suspension and provide similar serum levels of amoxicillin and clavulanic acid.</p>
<p><a name="INV-904152fb-1a67-4fe3-97fb-10c5021f71c0"></a>Amoxicillin serum concentrations achieved with amoxicillin and clavulanate potassium are similar to those produced by the oral administration of equivalent doses of amoxicillin alone. The half-life of amoxicillin after the oral administration of amoxicillin and clavulanate potassium is 1.3 hours and that of clavulanic acid is 1 hour. Time above the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> of 1 mcg/mL for amoxicillin has been shown to be similar after corresponding q12h and q8h dosing regimens of amoxicillin and clavulanate potassium in adults and children. Approximately 50% to 70% of the amoxicillin and approximately 25% to 40% of the clavulanic acid are excreted unchanged in urine during the first 6 hours after administration of 10 mL of amoxicillin and clavulanate potassium 250 mg/5 mL suspension.</p>
<p><a name="INV-a1fd3b6a-73c0-4715-b9a3-0540222533be"></a>Concurrent administration of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid.</p>
<p><a name="INV-d9bb3c8b-32ff-47c8-bf6b-fa8a03b91ece"></a>Neither component in amoxicillin and clavulanate potassium is highly protein-bound; clavulanic acid has been found to be approximately 25% bound to human serum and amoxicillin approximately 18% bound.</p>
<p><a name="INV-729a9efd-6de6-4f3d-8b6a-c350a2722709"></a>Amoxicillin diffuses readily into most body tissues and fluids with the exception of the brain and spinal fluid. The results of experiments involving the administration of clavulanic acid to animals suggest that this compound, like amoxicillin, is well distributed in body tissues.</p>
<p><a name="INV-5f2a1ac0-f13e-4c05-a9cb-ee0d7fbbb43e"></a>Two hours after oral administration of a single 35 mg/kg dose of amoxicillin and clavulanate potassium suspension to fasting children, average concentrations of 3 mcg/mL of amoxicillin and 0.5 mcg/mL of clavulanic acid were detected in <span class="product-label-link" type="condition" conceptid="4082782" conceptname="Fluid level behind tympanic membrane">middle ear effusions</span>.</p>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-a7cc1d99-f9ca-4981-8f14-f5909961cb18"></a><a name="section-4.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First"><a name="INV-7f850aca-efb0-4c2c-b51e-0d52fd441241"></a>Amoxicillin is a semisynthetic antibiotic with a broad spectrum of bactericidal activity against many gram-positive and gram-negative microorganisms. Amoxicillin is, however, susceptible to degradation by Î²-lactamases, and therefore, the spectrum of activity does not include organisms which produce these enzymes. Clavulanic acid is a Î²-lactam, structurally related to the penicillins, which possesses the ability to inactivate a wide range of Î²-lactamase enzymes commonly found in microorganisms resistant to penicillins and cephalosporins. In particular, it has good activity against the clinically important plasmid-mediated Î²-lactamases frequently responsible for transferred <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>.</p>
<p><a name="INV-ef050383-7bc6-479a-9a70-83958f137dbd"></a>The formulation of amoxicillin and clavulanic acid in amoxicillin and clavulanate potassium protects amoxicillin from degradation by Î²-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other Î²-lactam antibiotics. Thus, amoxicillin and clavulanate potassium possess the distinctive properties of a broad-spectrum antibiotic and a Î²-lactamase inhibitor.</p>
<p><a name="INV-163a8aaf-e9f9-4dfe-861a-b9ce54ec5c07"></a>Amoxicillin/clavulanic acid has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold">INDICATIONS AND USAGE</span>.</p>
<p><a name="INV-b6f9f4e3-b45c-4d0a-9590-19bcb8f008b7"></a><span class="Italics"><span class="Bold">	Gram-Positive Aerobes:</span></span></p>
<p><a name="INV-7c1ce2ac-9f4b-4d6d-97ec-370a249fc205"></a><span class="Italics">Staphylococcus aureus</span>(Î²-lactamase and non-Î²-lactamase-producing)Â§</p>
<p><a name="INV-05c32f2a-f50c-4494-865b-3938a579c290"></a><span class="Bold"><span class="Sup">Â§ </span></span>Staphylococci which are resistant to methicillin/oxacillin must be considered resistant to amoxicillin/clavulanic acid.</p>
<p><a name="INV-15074fdc-9a1a-402b-b5a0-622bdae55b6c"></a><span class="Italics"><span class="Bold">	Gram-Negative Aerobes:</span></span></p>
<p><a name="INV-d56c5989-e0f0-4418-93c3-71e82e62d706"></a><span class="Italics">Enterobacter</span>species (Although most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterobacter</span> species are resistant <span class="Italics">in vitro</span>, clinical efficacy has been demonstrated with amoxicillin and clavulanate potassium in <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> caused by these organisms.)</p>
<p><a name="INV-a0213791-fe5b-41de-acdf-0c4cf35dfcfb"></a><span class="Italics">Escherichia coli</span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-950ffbce-5858-419e-ac0f-dae99ddef2e3"></a><span class="Italics">Haemophilus influenzae</span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-fd9e0e90-a58a-47b1-b82e-2fd5ae26556d"></a><span class="Italics">Klebsiella</span>species (All known <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are Î²-lactamase-producing.)</p>
<p><a name="INV-0071bf2c-ae0c-46db-bf2e-45b527c92543"></a><span class="Italics">Moraxella catarrhalis</span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-f86506e1-0f6f-4039-bad3-f6df17e7187b"></a>The following <span class="Italics">in vitro</span> data are available, <span class="Bold"><span class="Underline">but their clinical significance is unknown.</span></span></p>
<p><a name="INV-3479e6f7-d50b-434f-9faf-4c3d45c68315"></a>Amoxicillin/clavulanic acid exhibits <span class="Italics">in vitro</span> minimal inhibitory concentrations (MICs) of 0.5 mcg/mL or less against most (â‰¥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Streptococcus pneumoniae</span><span class="Sup">â•‘</span>; MICs of 0.06 mcg/mL or less against most (â‰¥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Neisseria gonorrhoeae</span>; MICs of 4 mcg/mL or less against most (â‰¥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of staphylococci and anaerobic bacteria; and MICs of 8 mcg/mL or less against most (â‰¥ 90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of other listed organisms. However, with the exception of organisms shown to respond to amoxicillin alone, the safety and effectiveness of amoxicillin /clavulanic acid in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
<p><a name="INV-aae6a911-ad65-4710-bfda-df51c60a54b2"></a><span class="Sup">â•‘</span>Because amoxicillin has greater <span class="Italics">in vitro</span> activity against <span class="Italics">S.</span><span class="Italics">pneumoniae</span> than does ampicillin or penicillin, the majority of <span class="Italics">S. pneumoniae</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin.</p>
<p><a name="INV-b775826b-dcaf-4594-81c4-a7d95a539f81"></a><span class="Bold"><span class="Italics">	Gram-Positive Aerobes:</span></span></p>
<p><a name="INV-717f756c-ffbf-4be7-a2ed-a5520a2f91e2"></a><span class="Italics">Enterococcus faecalis</span><span class="Sup">Â¶ </span></p>
<p><a name="INV-f16752d5-c18d-45a0-8ab7-c5bc02db5865"></a><span class="Italics">Staphylococcus epidermidis </span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-1e47a6e2-63fc-468a-948a-393de0f6ad30"></a><span class="Italics">Staphylococcus saprophyticus </span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-6760e34b-9e76-4690-b97d-824852a2974a"></a><span class="Italics">Streptococcus pneumoniae</span><span class="Sup">Â¶**</span></p>
<p><a name="INV-5ec43a4c-4d8c-48d2-bc7e-d6cb7e4a5434"></a><span class="Italics">Streptococcus pyogenes</span><span class="Bold"><span class="Sup">Â¶**</span></span></p>
<p><a name="INV-010cb3ec-e521-4473-a527-b41cd535ed22"></a>viridans group Streptococcus <span class="Sup">Â¶**</span></p>
<p><a name="INV-c9ee7d49-c374-4b49-8627-5d6a579b957d"></a><span class="Bold"><span class="Italics">	Gram-Negative Aerobes:</span></span></p>
<p><a name="INV-b7a39599-c18b-4ebd-868a-125725eca3f7"></a><span class="Italics">Eikenella corrodens</span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-d92e4593-e284-457c-8f2c-29ffd2d621d9"></a><span class="Italics">Neisseria gonorrhoeae</span><span class="Sup">Â¶</span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-55286771-9436-477c-9424-2fe9f274ba6a"></a><span class="Italics">Proteus mirabilis</span><span class="Sup">Â¶</span>(Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-00a60aaf-a752-4096-8f0f-b30adf7a01ac"></a><span class="Bold"><span class="Italics">	Anaerobic Bacteria:</span></span></p>
<p><a name="INV-152816b8-598c-4ba5-bd74-e0066c8a4cce"></a><span class="Italics">Bacteroides</span>species, including <span class="Italics">Bacteroides fragilis</span> (Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-21639e54-6d39-49ba-8f56-61b5377cc536"></a><span class="Italics">Fusobacterium</span>species (Î²-lactamase and non-Î²-lactamase-producing)</p>
<p><a name="INV-d3d12372-c6a1-4e79-91ff-3e778e480cea"></a><span class="Italics">Peptostreptococcus</span>species <span class="Sup">**</span></p>
<p><a name="INV-540d694e-cc6f-413c-b8c4-65d18c9cdf37"></a><span class="Sup">Â¶ </span>Adequate and well-controlled clinical trials have established the effectiveness of amoxicillin alone in treating certain clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these organisms.</p>
<p><a name="INV-b523762f-444e-4383-b18a-82160ff36e26"></a><span class="Bold"><span class="Sup">**</span></span>These are non-Î²-producing organisms, and therefore, are susceptible to amoxicillin alone.</p>
<p><a name="INV-e4a54f3c-5b7d-47d3-8f1b-55af38ef1ce7"></a><span class="Bold">Susceptibility Testing:</span><span class="Italics"><span class="Bold">Dilution Techniques</span></span>: Quantitative methods are used to determine antimicrobial MICs. These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method <span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of amoxicillin/clavulanate potassium powder.</p>
<p><a name="INV-24256636-35c8-451d-9588-4bf27a0ace28"></a>The recommended dilution pattern utilizes a constant amoxicillin/clavulanate potassium ratio of 2 to 1 in all tubes with varying amounts of amoxicillin. MICs are expressed in terms of the amoxicillin concentration in the presence of clavulanic acid at a constant 2 parts amoxicillin to1 part clavulanic acid. The MIC values should be interpreted according to the following criteria:</p>
<p><a name="INV-3a6054f5-fcaa-4f33-a36a-b0f53b27c884"></a>RECOMMENDED RANGES FOR AMOXICILLIN /CLAVULANIC ACID SUSCEPTIBILITY TESTING</p>
<a name="INV-bb0d802d-f8d7-48b2-b53c-66ad642d8392"></a><table frame="void">
<caption><span>For Gram-Negative Enteric Aerobes:	</span></caption>
<col width="160px">
<col width="100px">
<col width="36px">
<col width="36px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center"><span class="Underline">MIC (mcg/mL)</span></td>
<td class="Botrule" colspan="2"><span class="Underline">Interpretation</span></td>
<td class="Botrule"> Â  </td>
</tr>
<tr>
<td class="Botrule" align="center"> â‰¤ 8/4 </td>
<td class="Botrule"> Susceptible </td>
<td class="Botrule" colspan="2"> (S)  </td>
</tr>
<tr>
<td class="Botrule" align="center"> 16/8 </td>
<td class="Botrule"> Intermediate </td>
<td class="Botrule" colspan="2"> (I) </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"> â‰¥ 32/16 </td>
<td class="Botrule"> Resistant </td>
<td class="Botrule" colspan="2"> (R) </td>
</tr>
</tbody>
</table>
<a name="INV-82d14460-f507-472d-ac32-5e23cafb9111"></a><table frame="void">
<caption><span>For Staphylococcus<span class="Sup">â€ â€ </span> and Haemophilus species:	</span></caption>
<col width="160px">
<col width="100px">
<col width="36px">
<col width="36px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center"><span class="Underline">MIC (mcg/mL)</span></td>
<td class="Botrule" colspan="2"><span class="Underline">Interpretation</span></td>
<td class="Botrule"> Â  </td>
</tr>
<tr>
<td class="Botrule" align="center">â‰¤ 4/2 </td>
<td class="Botrule"> Susceptible </td>
<td class="Botrule" colspan="2"> (S) </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">â‰¥ 8/4 </td>
<td class="Botrule"> Resistant </td>
<td class="Botrule" colspan="2"> (R) </td>
</tr>
</tbody>
</table>
<p><a name="INV-e0ef2f8d-e887-4f94-aca3-44f9404afe9c"></a><span class="Sup">â€ â€ </span>Staphylococci which are susceptible to amoxicillin/clavulanic acid but resistant to methicillin/oxacillin must be considered as resistant.</p>
<p><a name="INV-9e31515c-ce1e-4382-8181-f2aa79840528"></a><span class="Bold">For <span class="Italics">S. pneumoniae </span>from non-<span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> sources:</span>Isolates should be tested using amoxicillin/clavulanic acid and the following criteria should be used:</p>
<a name="INV-b893e81b-befa-4349-871e-2eb7c6086714"></a><table frame="void">
<col width="160px">
<col width="100px">
<col width="36px">
<col width="36px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center"><span class="Underline">MIC (mcg/mL)</span></td>
<td class="Botrule" colspan="2"><span class="Underline">Interpretation</span></td>
<td class="Botrule"> Â  </td>
</tr>
<tr>
<td class="Botrule" align="center"> â‰¤ 2/1 </td>
<td class="Botrule"> Susceptible </td>
<td class="Botrule" colspan="2"> (S)  </td>
</tr>
<tr>
<td class="Botrule" align="center"> 4/2 </td>
<td class="Botrule"> Intermediate </td>
<td class="Botrule" colspan="2"> (I) </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"> â‰¥ 8/4 </td>
<td class="Botrule"> Resistant </td>
<td class="Botrule" colspan="2"> (R) </td>
</tr>
</tbody>
</table>
<p><a name="INV-f7d30056-8242-480c-a74b-5fb18d690aff"></a>Note: These interpretive criteria are based on the recommended doses for respiratory tract</p>
<p><a name="INV-0662b868-5d59-4579-b242-cc0506e01d89"></a><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p><a name="INV-ca235e8d-955e-4f35-9c97-95e421f007e3"></a>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone that prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.</p>
<p><a name="INV-1f7863a2-903f-426e-9cf8-6411d8ebe3a5"></a>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard amoxicillin /clavulanate potassium powder should provide the following MIC values:</p>
<a name="INV-4d00f9a0-1610-441b-abc6-74d6181eba55"></a><table border="1" frame="border">
<col width="208px">
<col width="180px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule"><span class="Underline">Microorganism</span></td>
<td class="Botrule Rrule">
<span class="Underline">MIC</span><span class="Underline"> Range</span><span class="Underline"> (mcg/mL)</span><span class="Bold"><span class="Sup">â€¡â€¡</span></span>
</td>
</tr>
<tr>
<td class="Botrule Lrule">
<span class="Italics">E. coli</span> ATCC 25922 </td>
<td class="Botrule Rrule"> 2 to 8 </td>
</tr>
<tr>
<td class="Botrule Lrule">
<span class="Italics">E. coli</span> ATCC 35218 </td>
<td class="Botrule Rrule"> 4 to 16 </td>
</tr>
<tr>
<td class="Botrule Lrule">
<span class="Italics">E. faecalis</span> ATCC 29212 </td>
<td class="Botrule Rrule"> 0.25 to 1 </td>
</tr>
<tr>
<td class="Botrule Lrule">
<span class="Italics">H. influenzae</span> ATCC 49247 </td>
<td class="Botrule Rrule"> 2 to 16 </td>
</tr>
<tr>
<td class="Botrule Lrule">
<span class="Italics">S. aureus</span> ATCC 29213 </td>
<td class="Botrule Rrule"> 0.12 to 0.5 </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule">
<span class="Italics">S. pneumoniae</span> ATCC 49619 </td>
<td class="Botrule Rrule"> 0.03 to 0.12 </td>
</tr>
</tbody>
</table>
<p><a name="INV-2d35808e-44e8-468f-999a-6d3ddd900edc"></a><span class="Bold"><span class="Sup">â€¡â€¡</span></span>Expressed as concentration of amoxicillin in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid.</p>
<p><a name="INV-7a362aef-4735-4d17-96ce-7d16d4c3f8f6"></a><span class="Bold"><span class="Italics">Diffusion Techniques:</span></span>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure <span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg of amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) to test the susceptibility of microorganisms to amoxicillin/clavulanic acid.	</p>
<p><a name="INV-c54627bb-9bbb-49df-8f8b-d3c937f8d9c6"></a>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) disk should be interpreted according to the following criteria:</p>
<p><a name="INV-609e134e-f87c-48ea-a00d-86b571d62e8d"></a>RECOMMENDED RANGES FOR AMOXICILLIN/CLAVULANIC ACID SUSCEPTIBILITY TESTING</p>
<a name="INV-76bcec70-5ac1-4794-9471-5950edb04193"></a><table frame="void">
<caption><span>For Staphylococcus<span class="Sup">Â§Â§</span> species and H.influenzae <span class="Sup">a</span>:	</span></caption>
<col width="160px">
<col width="92px">
<col width="36px">
<col width="36px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center"><span class="Underline">Zone Diameter (mm)</span></td>
<td class="Botrule" colspan="2"><span class="Underline">Interpretation</span></td>
<td class="Botrule"> Â  </td>
</tr>
<tr>
<td class="Botrule" align="center"> â‰¥ 20 </td>
<td class="Botrule"> Susceptible </td>
<td class="Botrule" colspan="2"> (S) </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"> â‰¤ 19 </td>
<td class="Botrule"> Resistant </td>
<td class="Botrule" colspan="2"> (R) </td>
</tr>
</tbody>
</table>
<a name="INV-ca56446f-9c41-4425-b3c5-17e07e6de499"></a><table border="1" frame="border">
<caption><span>For Other Organisms Except S. pneumoniae<span class="Sup">b</span> and N. gonorrhoeae<span class="Sup">c</span>:	</span></caption>
<col width="156px">
<col width="96px">
<col width="36px">
<col width="36px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="center"><span class="Underline">Zone Diameter (mm)</span></td>
<td class="Botrule" colspan="2"><span class="Underline">Interpretation</span></td>
<td class="Botrule Rrule"> Â  </td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"> â‰¥ 18 </td>
<td class="Botrule"> Susceptible </td>
<td class="Botrule Rrule" colspan="2"> (S) </td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"> 14 to 17 </td>
<td class="Botrule"> Intermediate </td>
<td class="Botrule Rrule" colspan="2"> (I) </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center">â‰¤ 13 </td>
<td class="Botrule"> Resistant </td>
<td class="Botrule Rrule" colspan="2"> (R) </td>
</tr>
</tbody>
</table>
<p><a name="INV-925ec4bd-c97a-48d3-a1e3-e26ad4ddd848"></a><span class="Bold"><span class="Sup">Â§Â§</span></span>Staphylococci which are resistant to methicillin/oxacillin must be considered as resistant to amoxicillin/clavulanic acid.</p>
<p><a name="INV-23712111-c830-421d-b048-4a87dc41cd96"></a><span class="Sup">a</span>A broth microdilution method should be used for testing <span class="Italics">H. influenzae</span>. Beta-lactamase-negative, ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> must be considered resistant to amoxicillin/clavulanic acid.</p>
<p><a name="INV-8ecd7798-93c9-4aea-ac17-529d6b1daef7"></a><span class="Sup">b</span>Susceptibility of <span class="Italics">S. pneumoniae</span> should be determined using a 1 mcg oxacillin disk. Isolates with oxacillin zone sizes of â‰¥ 20 mm are susceptible to amoxicillin/clavulanic acid. An amoxicillin/clavulanic acid MIC should be determined on isolates of <span class="Italics">S. pneumoniae</span> with oxacillin zone sizes of â‰¤ 19 mm.</p>
<p><a name="INV-d03f9f76-a7a9-4888-9909-dab5a2440608"></a><span class="Sup">c</span>A broth microdilution method should be used for testing <span class="Italics">N. gonorrhoeae</span> and interpreted according to penicillin breakpoints.</p>
<p><a name="INV-ef6ec4d4-c0d6-4292-9ad4-9aac974d1942"></a>Interpretation should be as stated above for results using dilution techniques. Interpretation involves correlation of the diameter obtained in the disk test with the MIC for amoxicillin/clavulanic acid.</p>
<p><a name="INV-1fd4d89e-c278-45e6-970b-f27b2cae60da"></a>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures. For the diffusion technique, the 30 mcg amoxicillin/clavulanate potassium (20 mcg amoxicillin plus 10 mcg clavulanate potassium) disk should provide the following zone diameters in these laboratory quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="INV-3af60d82-0874-4126-ad94-2fb3b4c25ce8"></a><table frame="void">
<col width="196px">
<col width="156px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule"><span class="Underline">Microorganism </span></td>
<td class="Botrule"><span class="Underline">Zone Diameter (mm)</span></td>
</tr>
<tr>
<td class="Botrule">
<span class="Italics">E. coli</span> ATCC 25922  </td>
<td class="Botrule"> 19 to 25 mm </td>
</tr>
<tr>
<td class="Botrule">
<span class="Italics">E. coli</span> ATCC 35218  </td>
<td class="Botrule"> 18 to 22 mm </td>
</tr>
<tr class="Last">
<td class="Botrule">
<span class="Italics">S. aureus</span> ATCC 25923  </td>
<td class="Botrule"> 28 to 36 mm </td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-761cb577-8d9e-4aa7-a1ec-c8c4103795ea"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-0470199a-c3e8-41da-bea9-772c99a1dba6"></a>Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the conditions listed below:</p>
<p><a name="INV-4299d783-b3ab-4705-a32f-31505fa2b198"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span></span>- caused by Î²-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> and <span class="Italics">M. catarrhalis</span>.</p>
<p><a name="INV-01072d5b-513a-4c2c-9329-0bc6903db6bd"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span></span>- caused by Î²-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> and <span class="Italics">M. catarrhalis</span>.</p>
<p><a name="INV-972b96f5-87e8-40d7-a799-38f456a32034"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></span>- caused by Î²-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">H. influenzae</span> and <span class="Italics">M. catarrhalis</span>.</p>
<p><a name="INV-0b87b96f-abc5-48a5-b754-b9c57b7516b8"></a><span class="Bold">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span>- caused by Î²-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">S. aureus</span>, <span class="Italics">E. coli</span>, and <span class="Italics">Klebsiella</span> spp.</p>
<p><a name="INV-cc587ee6-cd8c-4d87-b3ad-fbd1f354e004"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></span>- caused by Î²-lactamase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">E. coli</span>, <span class="Italics">Klebsiella</span> spp. and <span class="Italics">Enterobacter</span> spp.</p>
<p><a name="INV-22b3d13b-2e99-4fa9-8a4d-0a8d81c91856"></a>While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by ampicillin-susceptible organisms and Î²-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater <span class="Italics">in vitro</span> activity against <span class="Italics">S. pneumoniae</span> than does ampicillin or penicillin, the majority of <span class="Italics">S. pneumoniae</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See <span class="Bold">Microbiology</span>.)</p>
<p><a name="INV-efad3ba7-c40e-48b7-823a-770930c2915e"></a>To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p><a name="INV-738c3ab0-dda2-4862-a37a-b4c47a9eceac"></a>Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-f1b2a965-609a-4058-943d-e32b66910f10"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-48098bb4-6704-4493-a1fd-5eb9ea555a5d"></a>Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) are contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any penicillin. It is also contraindicated in patients with a previous history of amoxicillin and clavulanate potassium associated <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="INV-a5dda182-0744-4b67-ae91-5ce5c3af01f8"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><a name="INV-43b48d92-02d3-4969-bbf0-dcd8088d0c15"></a>SERIOUS AND OCCASIONALLY FATAL <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS. BEFORE INITIATING THERAPY WITH AMOXICILLIN AND CLAVULANATE POTASSIUM, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> OCCURS AMOXICILLIN AND CLAVULANATE POTASSIUM SHOULD BE DISCONTINUED AND THE APPROPRIATE THERAPY INSTITUTED. <span class="Bold">SERIOUS <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ANAPHYLACTIC REACTIONS</span> REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE. OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED.</span></p>
<p><a name="INV-c8f01d21-2b22-42e1-beb9-1f4ff37a3c53"></a><span class="Italics">Clostridium difficile</span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including amoxicillin and clavulanate potassium, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><a name="INV-a2f71669-0a41-4795-836a-e33c64b1153b"></a><span class="Italics">C. difficile</span>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p><a name="INV-dc9d69ee-d002-4be1-ae04-0c0edcca2d43"></a>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p><a name="INV-21cfd143-d876-44c0-bc01-0b37a6643af3"></a>Amoxicillin and clavulanate potassium should be used with caution in patients with evidence of hepatic dysfunction. Hepatic toxicity associated with the use of amoxicillin and clavulanate potassium is usually reversible. On rare occasions, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported (less than 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications. (See <span class="Bold">CONTRAINDICATIONS</span> and <span class="Bold">ADVERSE REACTIONS</span> â€• <span class="Bold">Liver</span>.)</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="INV-9076f306-fc9a-494b-9462-235f1c8ca8ec"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><a name="INV-55214f33-4aa1-459b-b6af-e66801b41a84"></a><span class="Bold">General:</span>While amoxicillin and clavulanate potassium possesses the characteristic low toxicity of the penicillin group of antibiotics, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic function, is advisable during prolonged therapy.</p>
<p><a name="INV-536fc7e9-b0be-46ea-82fe-dd21c2ac92bb"></a>A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>. Thus, ampicillin-class antibiotics should not be administered to patients with mononucleosis.</p>
<p><a name="INV-3bfe094e-ecaa-4e21-925e-d54bb534e951"></a>The possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with mycotic or bacterial pathogens should be kept in mind during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur (usually involving <span class="Italics">Pseudomonas</span> or <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span>), the drug should be discontinued and/or appropriate therapy instituted.</p>
<p><a name="INV-04b10287-c7cf-40ad-8b9e-649d0c429430"></a>Prescribing amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="INV-34d1bcbc-901e-4a37-b2a6-8dfd31bdac30"></a><a name="section-8.1"></a><p></p>
<h2>Information for the Patient</h2>
<p class="First"><a name="INV-d2d4e933-e458-4043-ac00-415bd8282ebd"></a>Amoxicillin and clavulanate potassium may be taken every 8 hours or every 12 hours, depending on the strength of the product prescribed. Each dose should be taken with a meal or snack to reduce the possibility of <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">gastrointestinal upset</span>. Many antibiotics can cause <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. If <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is severe or lasts more than 2 or 3 days, call your doctor.</p>
<p><a name="INV-f1826a44-171b-4d89-ba58-ed9f369e309b"></a><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
<p><a name="INV-926b04ec-c3f1-4f43-9cd4-3d1ff7b8ad00"></a>Keep suspension refrigerated. Shake well before using. When dosing a child with amoxicillin and clavulanate potassium for oral suspension (liquid), use a dosing spoon or medicine dropper. Be sure to rinse the spoon or dropper after each use. Bottles of amoxicillin and clavulanate potassium for oral suspension may contain more liquid than required. Follow your doctorâ€™s instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine.</p>
<p><a name="INV-13babb79-d3e6-43e5-92d5-aa21a2c9475f"></a>Patients should be counseled that antibacterial drugs including amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) or other antibacterial drugs in the future.</p>
<p><a name="INV-9e70d878-33e7-40a7-be2f-175833faf332"></a><span class="Bold">Phenylketonurics</span></p>
<p><a name="INV-85d882c9-64dd-403b-80ad-ecd50c5c78f0"></a>Each 200 mg amoxicillin and clavulanate potassium chewable tablet contains 3.5 mg phenylalanine; each 400 mg chewable tablet contains 7 mg phenylalanine; each 5 mL of either the 200 mg/5 mL or 400 mg/5 mL oral suspension contains 7 mg phenylalanine. The other products of amoxicillin and clavulanate potassium do not contain phenylalanine and can be used by phenylketonurics. Contact your physician or pharmacist.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="INV-402e5541-4313-4a54-9102-6f3528247493"></a><a name="section-8.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First"><a name="INV-28f916e8-777e-47e7-bee5-32ea4169c764"></a>Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use with amoxicillin and clavulanate potassium may result in increased and prolonged blood levels of amoxicillin. Coadministration of probenecid cannot be recommended.</p>
<p><a name="INV-2f48fa1a-fb1d-42b4-8e96-c551446f4f7d"></a>The concurrent administration of allopurinol and ampicillin increases substantially the incidence of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> in patients receiving both drugs as compared to patients receiving ampicillin alone. It is not known whether this potentiation of ampicillin <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> is due to allopurinol or the <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span> present in these patients. There are no data with amoxicillin and clavulanate potassium and allopurinol administered concurrently.</p>
<p><a name="INV-fee2a4ee-78e6-45f5-9578-39444f135694"></a>In common with other broad-spectrum antibiotics, amoxicillin and clavulanate potassium may reduce the efficacy of oral contraceptives.</p>
</div>
<div class="Section">
<a name="INV-f3a263c7-3a3c-4b5b-ae9a-9dc3d47e8178"></a><a name="section-8.3"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First"><a name="INV-87538ba9-54ae-493b-96a6-6fc88eb8292f"></a>Oral administration of amoxicillin and clavulanate potassium will result in high urine concentrations of amoxicillin. High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using CLINITEST <span class="Sup">Â®</span>, Benedictâ€™s Solution, or Fehlingâ€™s Solution. Since this effect may also occur with amoxicillin and therefore amoxicillin and clavulanate potassium, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as CLINISTIX<span class="Sup">Â®</span>) be used.</p>
<p><a name="INV-7b6f2e5f-bf84-48e0-b539-3890eec9add2"></a>Following administration of ampicillin to pregnant women, a transient decrease in plasma concentration of total conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted. This effect may also occur with amoxicillin and therefore amoxicillin and clavulanate potassium.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="INV-430f55e8-4099-4166-98db-bbc5f4a94b58"></a><a name="section-8.4"></a><p></p>
<h2>Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First"><a name="INV-4c7b6b39-59cc-4f7b-9d35-7aa54777008e"></a>Long-term studies in animals have not been performed to evaluate carcinogenic potential.</p>
<p><a name="INV-49d727b0-5595-4272-87b5-6c6e7a43767b"></a><span class="Italics"><span class="Bold">Mutagenesis</span><span class="Bold">:</span></span>The mutagenic potential of amoxicillin and clavulanate potassium was investigated <span class="Italics">in vitro</span> with an Ames test, a human lymphocyte cytogenetic assay, a yeast test and a mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay, and <span class="Italics">in vivo</span> with mouse micronucleus tests and a dominant lethal test. All were negative apart from the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay where weak activity was found at very high, cytotoxic concentrations.</p>
<p><a name="INV-0e3855a9-2ad4-4ad5-9be5-f13ae84d4e1c"></a><span class="Italics"><span class="Bold">Impairment of Fertility:</span></span>Amoxicillin and clavulanate potassium at oral doses of up to 1,200 mg/kg/day (5.7 times the maximum human dose, 1,480 mg/m <span class="Sup">2</span>/day, based on body surface area) was found to have no effect on fertility and reproductive performance in rats, dosed with a 2:1 ratio formulation of amoxicillin:clavulanate.</p>
<p><a name="INV-d13cd785-0ae1-494b-9bb5-6e3a843366a8"></a><span class="Italics"><span class="Bold">Teratogenic effects:</span></span>Pregnancy (Category B). Reproduction studies performed in pregnant rats and mice given amoxicillin and clavulanate potassium at oral dosages up to 1,200 mg/kg/day, equivalent to 7,200 and 4,080 mg/m <span class="Sup">2</span>/day, respectively (4.9 and 2.8 times the maximum human oral dose based on body surface area), revealed no evidence of harm to the fetus due to amoxicillin and clavulanate potassium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="INV-15952073-eb88-4930-9bb8-9266f188ad40"></a><a name="section-8.5"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First"><a name="INV-e7c1bdfb-a51c-447d-9e67-e58014672841"></a>Oral ampicillin-class antibiotics are generally poorly absorbed during labor. Studies in guinea pigs have shown that intravenous administration of ampicillin decreased the uterine tone, frequency of contractions, height of contractions, and duration of contractions. However, it is not known whether the use of amoxicillin and clavulanate potassium in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary. In a single study in women with premature rupture of fetal membranes, it was reported that <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment with amoxicillin and clavulanate potassium may be associated with an increased risk of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> in neonates.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="INV-269f621c-89ad-4509-bc54-bf783339f3fd"></a><a name="section-8.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First"><a name="INV-989d862d-fb90-407a-bda2-0466a85e6340"></a>Ampicillin-class antibiotics are excreted in the milk; therefore, caution should be exercised when amoxicillin and clavulanate potassium is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="INV-41799c62-b44c-490d-b7fc-21ebada079ab"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First"><a name="INV-11dd6147-178b-4162-8fdc-0a03089137de"></a>Because of incompletely developed renal function in neonates and young infants, the elimination of amoxicillin may be delayed. Dosing of amoxicillin and clavulanate potassium should be modified in pediatric patients younger than 12 weeks (3 months). (See <span class="Bold">DOSAGE AND ADMINISTRATION</span>â€•<span class="Bold">Pediatric</span>.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-9388aa7f-9759-40be-8ca5-3ed178780a3a"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><a name="INV-c1d13e94-3faf-4b60-9a24-2bbb083827c1"></a>Amoxicillin and clavulanate potassium is generally well tolerated. The majority of side effects observed in clinical trials were of a mild and transient nature and less than 3% of patients discontinued therapy because of drug-related side effects. From the original premarketing studies, where both pediatric and adult patients were enrolled, the most frequently reported adverse effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (9%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (3%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (1%) and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (1%). The overall incidence of side effects, and in particular <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, increased with the higher recommended dose. Other less frequently reported reactions include: <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p><a name="INV-7db1e1b4-5ec1-4335-9954-7a68ba3ba036"></a>In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared amoxicillin and clavulanate potassium 45/6.4 mg/kg/day (divided q12h) for 10 days versus amoxicillin and clavulanate potassium 40/10 mg/kg/day (divided q8h) for 10 days in the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. A total of 575 patients were enrolled, and only the suspension formulations were used in this trial. Overall, the adverse event profile seen was comparable to that noted above; however, there were differences in the rates of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rashes</span>/<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and diaper area <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. (See <span class="Bold">CLINICAL STUDIES</span>.)</p>
<p><a name="INV-cdf69072-f654-4278-90a9-e0391ad49e2a"></a>The following adverse reactions have been reported for ampicillin-class antibiotics:</p>
<p><a name="INV-54fbab95-5a81-4be9-a329-b262882dfc9b"></a><span class="Bold">Gastrointestinal:</span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, black â€œhairyâ€? tongue, <span class="product-label-link" type="condition" conceptid="4104522" conceptname="Mucocutaneous candidiasis">mucocutaneous candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span>, and hemorrhagic/<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>. Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment. (See <span class="Bold">WARNINGS</span>.)</p>
<p><a name="INV-1244d634-2b96-4311-9350-1c6d85b6d96c"></a><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>:</span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rashes</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>-like reactions (<span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> accompanied by <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and frequently <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (rarely <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>), <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span>, and an occasional case of <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> (including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>) have been reported. These reactions may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, the drug should be discontinued, unless the opinion of the physician dictates otherwise. Serious and occasional fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions can occur with oral penicillin. (See <span class="Bold">WARNINGS</span>.)</p>
<p><a name="INV-5e35da59-f79f-47a1-b725-e94b12eb61e4"></a><span class="Bold">Liver:</span>A moderate rise in AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) and/or ALT (SGPT) has been noted in patients treated with ampicillin-class antibiotics, but the significance of these findings is unknown. Hepatic dysfunction, including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, (see <span class="Bold">CONTRAINDICATIONS</span>), increases in serum transaminases (AST and/or ALT), serum bilirubin and/or alkaline phosphatase, has been infrequently reported with amoxicillin and clavulanate potassium. It has been reported more commonly in the elderly, in males, or in patients on prolonged treatment. The histologic findings on liver biopsy have consisted of predominantly cholestatic, hepatocellular, or mixed cholestatic-hepatocellular changes. The onset of signs/symptoms of hepatic dysfunction may occur during or several weeks after therapy has been discontinued. The hepatic dysfunction, which may be severe, is usually reversible. On rare occasions, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported (less than 1 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> reported per estimated 4 million prescriptions worldwide). These have generally been cases associated with serious underlying diseases or concomitant medications. </p>
<p><a name="INV-877cd448-4b58-49ae-b860-459c76ecbd90"></a><span class="Bold">Renal:</span>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> have been reported rarely. <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> has also been reported (see <span class="Bold">OVERDOSAGE</span>).</p>
<p><a name="INV-618a4b1f-6c91-4263-9190-5aa88bfe9168"></a><span class="Bold">Hemic and Lymphatic Systems:</span><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported during therapy with penicillins. These reactions are usually reversible on discontinuation of therapy and are believed to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> phenomena. A slight <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> was noted in less than 1% of the patients treated with amoxicillin and clavulanate potassium. There have been reports of increased <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time in patients receiving amoxicillin and clavulanate potassium and anticoagulant therapy concomitantly.</p>
<p><a name="INV-8ab5ed0f-bd5b-41d0-9b77-4d1188674c38"></a><span class="Bold">Central Nervous System:</span><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, behavioral changes, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> have been reported rarely.</p>
<p><a name="INV-2a67b7e9-943c-4303-9d15-62e1784ae4d1"></a><span class="Bold">Miscellaneous:</span><span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> (brown, yellow, or gray staining) has been rarely reported. Most reports occurred in pediatric patients. Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="INV-6a847ca0-9d4d-4a00-8b3c-8a79d474123a"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><a name="INV-78b8256a-38f4-4e22-8e8e-96ddbbd02356"></a>Following overdosage, patients have experienced primarily <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> including stomach and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> have also been observed in a small number of patients.</p>
<p><a name="INV-388f5286-318f-4d2a-a5c1-aa6ea43045db"></a>In the case of overdosage, discontinue amoxicillin and clavulanate potassium, treat symptomatically, and institute supportive measures as required. If the overdosage is very recent and there is no contraindication, an attempt at <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or other means of removal of drug from the stomach may be performed. A prospective study of 51 pediatric patients at a poison center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying. <span class="Sup">3</span></p>
<p><a name="INV-36cef187-c6c0-4067-8dc9-c13fd557a039"></a>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> resulting in oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been reported in a small number of patients after overdosage with amoxicillin.</p>
<p><a name="INV-e0c36c2f-d5eb-48d7-89c0-dc76a4171352"></a><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span>, in some cases leading to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> should be maintained to reduce the risk of amoxicillin <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.</p>
<p><a name="INV-d9965d42-7585-4ac8-9006-511bea077979"></a><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> because of decreased renal clearance of both amoxicillin and clavulanate. Both amoxicillin and clavulanate are removed from the circulation by hemodialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-c48f68ae-cbe3-4c84-b1f6-e50cb5a7ff83"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><a name="INV-b5a60fff-db02-4b1b-8ecf-3dd5b8efb6e6"></a><span class="Bold">Dosage:	</span></p>
<p><a name="INV-770199d5-6ed2-41c9-9e86-58bb7c5bb3d5"></a><span class="Bold">Pediatric Patients:</span>Based on the amoxicillin component, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be dosed as follows:</p>
<p><a name="INV-a5ec4663-5bf6-4e23-8721-61527514a4cb"></a><span class="Bold">Neonates and infants aged &lt; 12 weeks (3 months):</span>Due to incompletely developed renal function affecting elimination of amoxicillin in this age group, the recommended dose of amoxicillin and clavulanate potassium is 30 mg/kg/day divided q12h, based on the amoxicillin component. Clavulanate elimination is unaltered in this age group. Experience with the 200 mg/5 mL formulation in this age group is limited and, thus, use of the 125 mg/5 mL oral suspension is recommended.</p>
<a name="INV-87ebda7b-f2a6-4cb8-9ddc-2349e41a0ceb"></a><table border="1" frame="border">
<caption><span>Patients aged 12 weeks (3 months) and older</span></caption>
<col width="280px">
<col width="144px">
<col width="168px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule" align="center" rowspan="2"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></span></td>
<td class="Botrule Rrule" align="center" colspan="2"><span class="Bold">DOSING REGIMEN</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><span class="Bold">q12h*</span></td>
<td class="Botrule Rrule" align="center"><span class="Bold">q8h</span></td>
</tr>
<tr>
<td class="Botrule Lrule"> Â  </td>
<td class="Botrule" align="center"> 200 mg/5 mL or
 400 mg/5 mL oral
 suspension<span class="Sup">â€ </span>
</td>
<td class="Botrule Rrule" align="center"> 125 mg/5 mL or
 250 mg/5 mL oral
 suspension </td>
</tr>
<tr>
<td class="Botrule Lrule"> <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span><span class="Sup">â€¡</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span>, and more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td class="Botrule" align="center"> Â 
 45 mg/kg/day q12h </td>
<td class="Botrule Rrule" align="center"> Â 
 40 mg/kg/day q8h </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"> Less severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> </td>
<td class="Botrule" align="center"> 25 mg/kg/day q12h </td>
<td class="Botrule Rrule" align="center"> 20 mg/kg/day q8h </td>
</tr>
</tbody>
</table>
<p><a name="INV-0d04adb1-670c-488c-9558-c44e20f9d7e1"></a><span class="Sup">*</span>The q12h regimen is recommended as it is associated with significantly less <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. (See <span class="Bold">CLINICAL STUDIES</span>.) However, the q12h formulations (200 mg and 400 mg) contain aspartame and should not be used by phenylketonurics.</p>
<p><a name="INV-0a3efd0d-d5b9-44c1-8106-488c3cd78d4f"></a><span class="Sup">â€ </span>Each strength of suspension of amoxicillin and clavulanate potassium is available as a chewable tablet for use by older children.</p>
<p><a name="INV-4f0b28b9-24a4-4421-b800-613cc488c776"></a><span class="Sup">â€¡</span>Duration of therapy studied and recommended for acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 10 days.</p>
<p><a name="INV-a59b6411-09cf-46e7-b98f-706d8fa88c2f"></a><span class="Bold"><span class="Italics">Pediatric Patients Weighing 40 kg and More:</span></span>Should be dosed according to the following adult recommendations: The usual adult dose is one amoxicillin 500 mg and clavulanate potassium tablet every 12 hours or one amoxicillin 250 mg and clavulanate potassium tablet every 8 hours. For more severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the respiratory tract, the dose should be one amoxicillin 875 mg and clavulanate potassium tablet every 12 hours or one amoxicillin 500 mg and clavulanate potassium tablet every 8 hours. Among adults treated with 875 mg every 12 hours, significantly fewer experienced severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or withdrawals with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> versus adults treated with 500 mg every 8 hours. For detailed adult dosage recommendations, please see complete prescribing information for amoxicillin and clavulanate potassium tablets.</p>
<p><a name="INV-9ad82a18-3f6f-4c86-a6bc-00046d80a5d6"></a>Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals. (See <span class="Bold">WARNINGS</span>.)</p>
<p><a name="INV-a128366e-babf-43f5-a4e9-3f3774507fdc"></a><span class="Bold"><span class="Italics">Adults:</span></span>Adults who have difficulty swallowing may be given the 125 mg/5 mL or 250 mg/5 mL suspension in place of the 500 mg tablet. The 200 mg/5 mL suspension or the 400 mg/5 mL suspension may be used in place of the 875 mg tablet. See dosage recommendations above for children weighing 40 kg or more.</p>
<p><a name="INV-0cbf881a-6446-47ad-b1bc-73bf9764350b"></a><span class="Bold">The </span><span class="Bold">amoxicillin/clavulanate potassium 250 mg tablet and the 250 mg chewable tablet do not contain the same amount of clavulanic acid (as the potassium salt). Amoxicillin/clavulanate potassium 250 mg tablet contains 125 mg of clavulanic acid, whereas the 250 mg chewable tablet contains 62.5 mg of clavulanic acid. Therefore, amoxicillin/clavulanate potassium 250 mg tablet and the 250 mg chewable tablet should <span class="Italics">not </span>be substituted for each other, as they are not interchangeable.</span></p>
<p><a name="INV-2a843490-3f39-4150-add9-c99cd3056dbc"></a><span class="Bold">Due to the different amoxicillin to clavulanic acid ratios in </span><span class="Bold">amoxicillin/clavulanate potassium 250 mg tablet (250/125) versus amoxicillin/clavulanate potassium 250 mg chewable tablet (250/62.5), amoxicillin/clavulanate potassium 250 mg tablet should not be used until the child weighs at least 40 kg and more.</span></p>
<p><a name="INV-fc2cc0d4-e6a8-4aec-9964-cf4a56842aa3"></a><span class="Bold">Directions for Mixing Oral Suspension: </span>Prepare a suspension at time of dispensing as follows: Tap bottle until all the powder flows freely. Add approximately 2/3 of the total amount of water for reconstitution (see table below) and shake vigorously to suspend powder. Add remainder of the water and again shake vigorously.</p>
<a name="INV-2104b534-a092-46fb-92ac-4d6c070a11fa"></a><table frame="void">
<caption><span>Amoxicillin/Clavulanate Potassium for Oral Suspension, 200 mg/5 mL</span></caption>
<col width="168px">
<col width="192px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center"> Â 
 Bottle Size </td>
<td class="Botrule" align="center"> Amount of Water Required for Reconstitution </td>
</tr>
<tr>
<td class="Botrule" align="center"> 50 mL </td>
<td class="Botrule" align="center"> 47 mL </td>
</tr>
<tr>
<td class="Botrule" align="center"> 75 mL </td>
<td class="Botrule" align="center"> 70 mL </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"> 100 mL </td>
<td class="Botrule" align="center"> 94 mL </td>
</tr>
</tbody>
</table>
<p><a name="INV-d4777393-9c3d-417e-97ca-9f5b0669799e"></a>Each teaspoonful (5 mL) will contain 200 mg amoxicillin and 28.5 mg clavulanic acid as the potassium salt.</p>
<a name="INV-5ab93a04-8265-4397-a11b-53ef8441ec37"></a><table frame="void">
<caption><span>Amoxicillin/Clavulanate Potassium for Oral Suspension, 400 mg/5 mL</span></caption>
<col width="168px">
<col width="192px">
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center"> Â 
 Bottle Size </td>
<td class="Botrule" align="center"> Amount of Water Required for Reconstitution </td>
</tr>
<tr>
<td class="Botrule" align="center"> 50 mL </td>
<td class="Botrule" align="center"> 46 mL </td>
</tr>
<tr>
<td class="Botrule" align="center"> 75 mL </td>
<td class="Botrule" align="center"> 68 mL </td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"> 100 mL </td>
<td class="Botrule" align="center"> 90 mL </td>
</tr>
</tbody>
</table>
<p><a name="INV-0f0c8732-f44a-4ac3-9fef-5be2f9fae801"></a>Each teaspoonful (5 mL) will contain 400 mg amoxicillin and 57 mg clavulanic acid as the potassium salt.</p>
<p><a name="INV-a388fbfc-4f1a-4951-a990-19e390155519"></a><span class="Bold">Note:</span>SHAKE ORAL SUSPENSION WELL BEFORE USING.</p>
<p><a name="INV-ed3b390a-0567-4b9b-b661-560ab54ca9b8"></a><span class="Bold">Reconstituted suspension must be stored under refrigeration and discarded after 10 days.</span></p>
<p><a name="INV-687f1775-6445-4961-a883-a6dbe3c61ddc"></a><span class="Bold">Administration:</span>Amoxicillin and clavulanate potassium may be taken without regard to meals; however, absorption of clavulanate potassium is enhanced when amoxicillin and clavulanate potassium is administered at the start of a meal. To minimize the potential for gastrointestinal intolerance, amoxicillin and clavulanate potassium should be taken at the start of a meal.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-871a979f-fc3a-449a-8cfa-a66c921f496d"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><a name="INV-2769454d-39a9-4531-becc-163fab2fefd5"></a><span class="Bold">Amoxicillin and Clavulanate Potassium For Oral Suspension, USP</span></p>
<p><a name="INV-70581f5f-14b7-4947-9b49-11c9c9e76b8f"></a><span class="Bold">200 mg/5 mL</span></p>
<p><a name="INV-80dfa12b-40d0-4931-b14d-c75a7fc8473b"></a>Each 5 mL of reconstituted white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow colored, strawberry flavored suspension contains 200 mg of amoxicillin and 28.5 mg of clavulanic acid as the potassium salt and is available as follows:</p>
<p><a name="INV-45bbd3fe-685c-425b-9a35-8cac0208787d"></a>NDC 63304-977-03 50 mL bottles</p>
<p><a name="INV-8379bbd8-0d06-4ea2-8677-e5b6b1dc7dfe"></a>NDC 63304-977-01 75 mL bottles</p>
<p><a name="INV-038b6975-2c31-4ae4-b640-4b45ab5aa42f"></a>NDC 63304-977-04 100 mL bottles</p>
<p><a name="INV-5a1be90d-7eaa-4720-b1e5-cef671728483"></a><span class="Bold">400 mg/5 mL</span></p>
<p><a name="INV-ca200337-a515-4ff0-8deb-0e41dcce6c6a"></a>Each 5 mL of reconstituted white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow colored, strawberry flavored suspension contains 400 mg of amoxicillin and 57 mg of clavulanic acid as the potassium salt and is available as follows:</p>
<p><a name="INV-4aedae04-c4af-4c78-a82e-042a6a864ef8"></a>NDC 63304-979-03 50 mL bottles</p>
<p><a name="INV-beb4d36e-09bd-4123-9a5c-29211c6803b1"></a>NDC 63304-979-01 75 mL bottles</p>
<p><a name="INV-8c84e1a7-9fd6-4f78-badc-9e18b29cfbde"></a>NDC 63304-979-04 100 mL bottles</p>
<p><a name="INV-68f8049e-43a4-4bb6-b304-256f77d483d8"></a><span class="Bold">Amoxicillin and Clavulanate Potassium Tablets, USP (Chewable):</span></p>
<p><a name="INV-d126e775-018e-4d41-ae1e-1444e99ac980"></a><span class="Bold">200 mg/ 28.5 mg</span></p>
<p><a name="INV-87939b29-b20a-44ed-a8e5-17f37844dbb7"></a>Amoxicillin and clavulanate potassium tablets (chewable) 200 mg/28.5 mg contain 200 mg of amoxicillin as the trihydrate and 28.5 mg of clavulanic acid as clavulanate potassium. Each tablet is a pink colored, circular, biconvex, mottled tablet, debossed with â€˜RX753â€™ on one side and plain on the other side.</p>
<p><a name="INV-7da2ec3e-89b6-4b73-8d77-6a6e91d201b0"></a>NDC 63304-753-03 Bottles of 10</p>
<p><a name="INV-a92b4adc-129c-412d-8af5-d5e507c377e9"></a>NDC 63304-753-20 Bottles of 20</p>
<p><a name="INV-0d47f9be-0e06-4b1e-9bdf-b77688b5e11a"></a>NDC 63304-753-01 Bottles of 100</p>
<p><a name="INV-2bef450b-217c-4741-a69d-29d74aee8116"></a>NDC 63304-753-21 Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packs of 20</p>
<p><a name="INV-ce9c7c73-9e5d-4a3f-9329-24d00e7d1522"></a><span class="Bold">400 mg/57 mg</span></p>
<p><a name="INV-20dc81be-d06b-47ad-aaeb-6c087046956f"></a>Amoxicillin and clavulanate potassium tablets (chewable) 400 mg/57 mg contain 400 mg of amoxicillin as the trihydrate and 57 mg of clavulanic acid as clavulanate potassium. Each tablet is a pink colored, circular, biconvex, mottled tablet, debossed with â€˜RX754â€™ on one side and plain on the other side.</p>
<p><a name="INV-0b423bab-c75c-4885-9a17-bc4f7f579976"></a>NDC 63304-754-03 Bottles of 10</p>
<p><a name="INV-e5e9664d-b086-47d0-8582-8a396c0bcd00"></a>NDC 63304-754-20 Bottles of 20</p>
<p><a name="INV-8b187c8e-9b25-4886-859d-f00e1c86768d"></a>NDC 63304-754-01 Bottles of 100</p>
<p><a name="INV-88296e28-3d86-422a-9f2f-f71281371382"></a>NDC 63304-754-21 Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Packs of 20</p>
<p><a name="INV-f3000ab9-54e8-49e5-8ec5-19387d530b64"></a>Store dry powder and tablets at 20 - 25Â° C (68 - 77Â° F). (See USP Controlled Room Temperature). Dispense in tightly closed, moisture-proof containers. Store reconstituted suspension under refrigeration. Discard unused suspension after 10 days.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="INV-4fb87268-864f-4eb8-8087-8b098f22e57a"></a><a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"><a name="INV-bd0101f9-a7fd-4952-a8bf-3cc6591eff7d"></a>In pediatric patients (aged 2 months to 12 years), 1 US/Canadian clinical trial was conducted which compared amoxicillin/ clavulanate potassium 45/6.4 mg/kg/day (divided q12h) for 10 days versus amoxicillin/clavulanate potassium 40/10 mg/kg/day (divided q8h) for 10 days in the treatment of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>. Only the suspension formulations were used in this trial. A total of 575 patients were enrolled, with an even distribution among the 2 treatment groups and a comparable number of patients were evaluable (i.e., â‰¥ 84%) per treatment group. Strict <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>-specific criteria were required for eligibility and a strong correlation was found at the end of therapy and follow-up between these criteria and physician assessment of clinical response. The clinical efficacy rates at the end of therapy visit (defined as 2 to 4 days after the completion of therapy) and at the follow-up visit (defined as 22to 28 days post-completion of therapy) were comparable for the 2 treatment groups, with the following cure rates obtained for the evaluable patients: At end of therapy, 87.2% (n = 265) and 82.3% (n = 260) for 45 mg/kg/day q12h and 40 mg/kg/day q8h, respectively. At follow-up, 67.1% (n = 249) and 68.7% (n = 243) for 45 mg/kg/day q12h and 40 mg/kg/day q8h, respectively.</p>
<p><a name="INV-fa9d3ee1-ba97-4538-a9a9-6b665ef450a3"></a>The incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <span class="Sup">â€ â€ â€ </span> was significantly lower in patients in the q12h treatment group compared to patients who received the q8h regimen (14.3% and 34.3%, respectively). In addition, the number of patients with either severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or who were withdrawn with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was significantly lower in the q12h treatment group (3.1% and 7.6% for the q12h/10 day and q8h/10 day, respectively). In the q12h treatment group, 3 patients (1%) were withdrawn with an</p>
<p><a name="INV-b73cfcb4-349f-4f47-9892-68fa143b3b27"></a><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, while 1 patient (0.3%) in the q8h group was withdrawn for this reason. The number of patients with a <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidal infection</span> of the diaper area was 3.8% and 6.2% for the q12h and q8h groups, respectively.</p>
<p><a name="INV-98f070fa-e009-464f-af77-c5820a4f889c"></a>It is not known if the finding of a statistically significant reduction in <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> with the oral suspensions dosed q12h, versus suspensions dosed q8h, can be extrapolated to the chewable tablets. The presence of mannitol in the chewable tablets may contribute to a different <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> profile. The q12h oral suspensions are sweetened with aspartame only.</p>
<p><a name="INV-99223d2c-400d-4a0e-9611-0d8213001465"></a><span class="Sup">â€ â€ â€ </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was defined as either: (a) 3 or more watery or 4 or more loose/watery stools in 1 day; OR (b) 2 watery stools per day or 3 loose/watery stools per day for 2 consecutive days.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="INV-c007e7d4-16bd-440b-8c71-0af2d378e892"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<p class="First"><a name="INV-e84b2bdd-a58b-4587-bd3a-9e4565cea3c3"></a>1. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Third Edition. Approved Standard NCCLS Document M7-A3, Vol. 13, No. 25. NCCLS, Villanova, PA, Dec. 1993.</p>
<p><a name="INV-e2d1cdb1-a3e6-4e75-8994-1aff2bd64583"></a>2. National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Disk Susceptibility Tests-Fifth Edition. Approved Standard NCCLS Document M2-A5, Vol. 13, No. 24. NCCLS, Villanova, PA, Dec. 1993.</p>
<p><a name="INV-e7b8e97b-271e-4781-a887-2d59c318ff25"></a>3. Swanson-Biearman B, Dean BS, Lopez G, Krenzelok EP. The effects of penicillin and cephalosporin ingestions in children less than six years of age. <span class="Italics">Vet Hum Toxicol </span>1988;30:66-67.</p>
<p><a name="INV-f7a1d399-0203-4a01-8739-53c139f9b2de"></a>CLINITEST is a registered trademark of Miles, Inc.</p>
<p><a name="INV-b7b334be-a08e-4bfa-843d-1f616fd61aef"></a>CLINISTIX is a registered trademark of Bayer Corporation.</p>
<p><a name="INV-d426516e-9267-4442-ae7b-39f771d84d44"></a>Manufactured for:</p>
<p><a name="INV-bbf15c1a-670a-42a3-a0aa-19f5ec8bcab4"></a>Ranbaxy Pharmaceuticals Inc.</p>
<p><a name="INV-da05704f-e00e-4a80-8ebb-130055d9dbda"></a>Jacksonville, FL 32257 USA</p>
<p><a name="INV-d5ea3b9c-6ac4-49d1-93e0-0680b37006fc"></a>by: Ranbaxy Laboratories Limited</p>
<p><a name="INV-5768d2d0-f2bc-45ca-85aa-78fb40a0193e"></a>New Delhi â€“ 110 019, India</p>
<p><a name="INV-f09883b4-84b1-4aec-9357-a6a08a388b08"></a>April 2008</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMOXICILLIN AND CLAVULANATE POTASSIUMÂ 		
					</strong><br><span class="contentTableReg">amoxicillin and clavulanate potassium powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-977</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Amoxicillin</strong> (Amoxicillin) </td>
<td class="formItem"></td>
<td class="formItem">200Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Clavulanate potassium</strong> (Clavulanic acid) </td>
<td class="formItem"></td>
<td class="formItem">28.5Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Aspartame</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Colloidal silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Flavor strawberry</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Flavor strawberry guarana</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Monosodium citrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium citrate( as dihydrate)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Xanthan gum</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-977-03</td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63304-977-01</td>
<td class="formItem">75 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63304-977-04</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMOXICILLIN AND CLAVULANATE POTASSIUMÂ 		
					</strong><br><span class="contentTableReg">amoxicillin and clavulanate potassium powder, for suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-979</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Amoxicillin</strong> (Amoxicillin) </td>
<td class="formItem"></td>
<td class="formItem">400Â mg Â inÂ 5Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Clavulanate potassium</strong> (Clavulanic acid) </td>
<td class="formItem"></td>
<td class="formItem">57Â mg Â inÂ 5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Aspartame</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Colloidal silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Flavor strawberry</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Flavor strawberry guarana</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Monosodium citrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium citrate( as dihydrate)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Xanthan gum</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-979-03</td>
<td class="formItem">50 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63304-979-01</td>
<td class="formItem">75 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63304-979-04</td>
<td class="formItem">100 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMOXICILLIN AND CLAVULANATE POTASSIUMÂ 		
					</strong><br><span class="contentTableReg">amoxicillin and clavulanate potassium tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-753</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Amoxicillin</strong> (Amoxicillin) </td>
<td class="formItem"></td>
<td class="formItem">200Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Clavulanate potassium</strong> (Clavulanic acid) </td>
<td class="formItem"></td>
<td class="formItem">28.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Aspartame</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C red No. 40 aluminum lake</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glycine</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Povidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mint cream flavor</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Orange cream flavor</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium starch glycolate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Tropical blend flavor</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">score with uneven pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX753</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-753-03</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63304-753-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63304-753-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:63304-753-21</td>
<td class="formItem">20  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AMOXICILLIN AND CLAVULANATE POTASSIUMÂ 		
					</strong><br><span class="contentTableReg">amoxicillin and clavulanate potassium tablet, chewable</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63304-754</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Amoxicillin</strong> (Amoxicillin) </td>
<td class="formItem"></td>
<td class="formItem">400Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>Clavulanate potassium</strong> (Clavulanic acid) </td>
<td class="formItem"></td>
<td class="formItem">57Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Aspartame</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C red No. 40 aluminum lake</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glycine</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Povidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Mannitol</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Mint cream flavor</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Orange cream flavor</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium starch glycolate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Tropical blend flavor</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">score with uneven pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RX754</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Coating</td>
<td class="formItem">false</td>
<td class="formLabel">Symbol</td>
<td class="formItem">false</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63304-754-03</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63304-754-20</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:63304-754-01</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:63304-754-21</td>
<td class="formItem">20  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Ranbaxy Pharmaceuticals Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>21209BCF-E831-B3D6-7F05-992BFCDE3889</div>
<div>Set id: b897c800-24a2-4e76-8668-498c5515c3d0</div>
<div>Version: 1</div>
<div>Effective Time: 20080501</div>
</div>
</div>Â <div class="DistributorName">Ranbaxy Pharmaceuticals Inc.</div></p>
</body></html>
